answersLogoWhite

0

AllQ&AStudy Guides
Best answer

fondaparinux

This answer is:
Related answers

fondaparinux

View page

Arixtra

View page

Fondaparinux is C31H43N3Na10O49S8 has a molecular mass of 1726.77 a.m.u. as 'deca-sodium salt' !!

Name:

2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→ 4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2- (sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranouronosyl-(1→ 4)-O-methyl-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranoside, decasodium salt

View page

In the US, a drug patent lasts twenty years, if patented after 1995 (17years prior). New drugs usually have multiple patients covering numerous aspects of the agent and the manufacturing process. Generics can be introduced after the patent expires. However, the drug companies apply for the patent when the drug is discovered, then it has to be studied to prove safety and efficacy before the drug reaches the market (5-10years) A generic version typically appears 7-10 years after the patented version. Originators typically sue generic companies over a number of years to protect their patents. Originators also have been granted patent extensions under special circumstances.

View page

1. Diagnosis

  • Ask patient for medical history
  • Physical examine (look for swelling, warmth and redness)
  • D-dimer test (reference: <250ng/mL)
  • Ultrasound
  • If ultrasound was inconclusive then venography
  • If venography isn't possible MRI

2. Treatment

Drug administration:

  • Unfractionated heparin
  • Low molecular weight heparin (enoxaparin/Lovenox, dalteparin/Fragmin, or tinzaparin/Innohep)
  • Fondaparinux (Arixtra)
Walking/movement
View page
Featured study guide
📓
See all Study Guides
✍️
Create a Study Guide
Search results